[go: up one dir, main page]

MX2021009328A - Vectores moleculares estructurados y usos de los mismos. - Google Patents

Vectores moleculares estructurados y usos de los mismos.

Info

Publication number
MX2021009328A
MX2021009328A MX2021009328A MX2021009328A MX2021009328A MX 2021009328 A MX2021009328 A MX 2021009328A MX 2021009328 A MX2021009328 A MX 2021009328A MX 2021009328 A MX2021009328 A MX 2021009328A MX 2021009328 A MX2021009328 A MX 2021009328A
Authority
MX
Mexico
Prior art keywords
disease
pharmaceutical compositions
inflammatory compounds
compounds
structured molecular
Prior art date
Application number
MX2021009328A
Other languages
English (en)
Inventor
Jacques Bodennec
Amor Belmeguenaï
Selena Bodennec
Laurent Bezin
Béatrice Georges
Victor Blot
Original Assignee
Univ Claude Bernard Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Claude Bernard Lyon filed Critical Univ Claude Bernard Lyon
Publication of MX2021009328A publication Critical patent/MX2021009328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C07F9/4009—Esters containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A23L29/04—Fatty acids or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ophthalmology & Optometry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a vectores moleculares estructurados de fórmula (I), compuestos de fórmula (II) y composiciones farmacéuticas que comprenden dichos compuestos. La invención también se refiere a dichas composiciones farmacéuticas para su uso para prevenir y/o tratar una enfermedad elegida de una enfermedad inflamatoria o una enfermedad asociada a un trastorno cognitivo. La invención se refiere además a dichas composiciones farmacéuticas para su uso para prevenir el deterioro cognitivo o restablecer las funciones cognitivas alteradas en lesiones cerebrales y/o en lesiones cerebrales traumáticas y/o en una enfermedad neuroinflamatoria, y/o en una enfermedad neurodegenerativa.
MX2021009328A 2019-02-21 2020-02-21 Vectores moleculares estructurados y usos de los mismos. MX2021009328A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305212 2019-02-21
EP19306376 2019-10-23
PCT/EP2020/054662 WO2020169822A1 (en) 2019-02-21 2020-02-21 Structured molecular vectors for anti-inflammatory compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2021009328A true MX2021009328A (es) 2021-11-12

Family

ID=69593711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009328A MX2021009328A (es) 2019-02-21 2020-02-21 Vectores moleculares estructurados y usos de los mismos.

Country Status (12)

Country Link
US (1) US20220162239A1 (es)
EP (1) EP3927348A1 (es)
JP (1) JP7579266B2 (es)
KR (2) KR102411189B1 (es)
CN (1) CN113677349B (es)
AU (1) AU2020225354B2 (es)
BR (1) BR112021015307A2 (es)
CA (1) CA3126203A1 (es)
IL (1) IL284712A (es)
MX (1) MX2021009328A (es)
SG (1) SG11202107578QA (es)
WO (1) WO2020169822A1 (es)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993067A (en) * 1959-05-29 1961-07-18 Upjohn Co Phosphonates, acid derivatives thereof and their salts
DE3435156A1 (de) * 1984-09-25 1986-04-03 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung der stereoisomeren von 1-amino-alkylphosphonsaeuren oder 1-aminoalkylphosphinsaeuren
HU203360B (en) * 1988-11-25 1991-07-29 Monsanto Co Process for producing n-acylamino methylphosphonates
GB2323089B (en) * 1996-04-12 1999-02-10 Lovesgrove Res Ltd Method for preparing organo phosphonic compounds
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
WO2002004467A1 (en) * 2000-07-12 2002-01-17 Ardenia Investments Ltd. Novel cytotoxic compounds and their use
AU2001296536A1 (en) * 2000-10-03 2002-04-15 University Of Virginian Patent Foundation Novel lysophosphatidic acid receptor agonists and antagonists
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1469083A1 (en) 2003-04-17 2004-10-20 Centre National De La Recherche Scientifique (Cnrs) Method of calibration of reverse transcription using a synthetic messenger RNA (smRNA) as an internal control
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
WO2005115150A2 (en) * 2004-05-06 2005-12-08 University Of Virginia Patent Foundation Novel lysophosphatidic acid receptor selective antagonists
KR20080052665A (ko) * 2005-09-15 2008-06-11 페인셉터 파마 코포레이션 뉴로트로핀 매개 활성 조절 방법
JP5552314B2 (ja) * 2006-11-01 2014-07-16 プロノヴァ バイオファーマ ノルゲ アーエス 新規脂質化合物
CN102970972B (zh) * 2010-03-15 2015-12-16 安雷戚·迪兹 硝基羧酸用于治疗、诊断和预防侵袭性愈合模式的用途
EP2629609A4 (en) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
CA2946275A1 (en) * 2014-04-04 2015-10-08 Osaka University Drug delivery enhancer comprising substance for activating lysophospholipid receptors
WO2018071679A1 (en) * 2016-10-13 2018-04-19 Carnot, Llc N-acylethanolamide derivatives and uses thereof
FR3063645B1 (fr) 2017-03-08 2021-06-11 Lipther Acefapc pour le traitement des maladies acetylcholine dependantes
US20180303821A1 (en) * 2017-04-24 2018-10-25 BraneQuest, Inc. Membrane active molecules

Also Published As

Publication number Publication date
AU2020225354A8 (en) 2021-09-02
AU2020225354A1 (en) 2021-08-12
AU2020225354B2 (en) 2025-03-06
JP7579266B2 (ja) 2024-11-07
KR20220082117A (ko) 2022-06-16
SG11202107578QA (en) 2021-08-30
JP2022521414A (ja) 2022-04-07
IL284712A (en) 2021-08-31
BR112021015307A2 (pt) 2021-11-09
EP3927348A1 (en) 2021-12-29
CN113677349A (zh) 2021-11-19
KR102411189B1 (ko) 2022-06-23
WO2020169822A1 (en) 2020-08-27
CA3126203A1 (en) 2020-08-27
CN113677349B (zh) 2024-03-19
US20220162239A1 (en) 2022-05-26
KR20210042385A (ko) 2021-04-19

Similar Documents

Publication Publication Date Title
ZA202403923B (en) Heterocyclic compounds as immunomodulators
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MY200962A (en) Amide Derivatives As Nav1.7 And Nav1.8 Blockers
MX2019008875A (es) Composiciones de inhibidor del canal crac.
NZ737536A (en) Substituted benzamides and methods of use thereof
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2021007425A (es) Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8.
ZA202006071B (en) Antiproliferation compounds and uses thereof
EA202192047A1 (ru) Соединения и их применение
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
MX2021009328A (es) Vectores moleculares estructurados y usos de los mismos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MX2022003816A (es) Compuestos antibacterianos.
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
SA521422315B1 (ar) ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها
PH12017501668A1 (en) Bace1 inhibitors
EA202192313A1 (ru) Структурированные молекулярные векторы для противовоспалительных соединений и их применение